Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Virios Therapeutics Inc (VIRI)

Virios Therapeutics Inc (VIRI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,506
  • Shares Outstanding, K 19,258
  • Annual Sales, $ 0 K
  • Annual Income, $ -5,300 K
  • 60-Month Beta 1.61
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.56
Trade VIRI with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.27
  • Most Recent Earnings $-0.07 on 05/09/24
  • Next Earnings Date 08/08/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 100.52%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 1,389.95% on 04/15/24
  • IV Low 0.00% on 07/03/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 10
  • Volume Avg (30-Day) 20
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 318
  • Open Int (30-Day) 460

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.07
  • Number of Estimates 2
  • High Estimate -0.07
  • Low Estimate -0.07
  • Prior Year -0.08
  • Growth Rate Est. (year over year) +12.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2090 +14.88%
on 07/01/24
0.3758 -36.11%
on 06/05/24
+0.0191 (+8.64%)
since 06/03/24
3-Month
0.1557 +54.21%
on 05/23/24
0.5292 -54.63%
on 04/15/24
-0.2519 (-51.20%)
since 04/03/24
52-Week
0.1557 +54.21%
on 05/23/24
2.4200 -90.08%
on 07/14/23
-1.1199 (-82.35%)
since 07/03/23

Most Recent Stories

More News
Virios Therapeutics Up 75% on Fibromyalgia Phase 3 Proposal

Virios Therapeutics Inc. (NASDAQ: VIRI) is a developmental-stage biotechnology company specializing in novel antiviral therapies for treating fibromyalgia

VIRI : 0.2401 (+2.61%)
AGN : 193.02 (+0.02%)
LLY : 898.10 (-0.95%)
PFE : 27.70 (-0.47%)
GPS : 23.88 (+3.83%)
Virios Therapeutics, Inc. to Present at the Virtual Planet MicroCap Showcase

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia...

VIRI : 0.2401 (+2.61%)
Virios Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update

Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases...

VIRI : 0.2401 (+2.61%)
Virios Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Monday, November 14, 2022

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia...

VIRI : 0.2401 (+2.61%)
Virios Therapeutics, Inc. Announces Closing of Public Offering

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia,...

VIRI : 0.2401 (+2.61%)
Pre-Market Brief: Stocks Mixed Ahead Of FOMC Meeting

December S&P 500 futures (ESZ22) are moderately down -0.08% this morning after three major US benchmark indices rebounded from 9-week lows to close higher during the regular session as market participants...

ESZ22 : 3,871.47s (-0.66%)
F : 12.87 (unch)
GM : 46.71 (-0.51%)
VIRI : 0.2401 (+2.61%)
ENVX : 15.28 (+7.68%)
CGNX : 47.16 (-0.06%)
CHNG : 27.49 (+0.26%)
UNH : 489.89 (-1.68%)
Virios Therapeutics, Inc. Announces Pricing of Public Offering

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia,...

VIRI : 0.2401 (+2.61%)
Virios Therapeutics, Inc. Announces Proposed Public Offering

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia,...

VIRI : 0.2401 (+2.61%)
Virios Therapeutics Announces Top-Line Results from Phase 2b Study of IMC-1 in Fibromyalgia

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia...

VIRI : 0.2401 (+2.61%)
Virios Therapeutics’ Announces Dosing of First Patient in IMC-2 Long-COVID Treatment Trial

Virios Therapeutics, Inc. (Nasdaq: VIRI ), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia...

VIRI : 0.2401 (+2.61%)

Business Summary

Virios Therapeutics Inc. is a biotechnology company. It is focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. Virios Therapeutics Inc. is based in Alpharetta, Georgia.

See More

Key Turning Points

3rd Resistance Point 0.2794
2nd Resistance Point 0.2667
1st Resistance Point 0.2534
Last Price 0.2401
1st Support Level 0.2274
2nd Support Level 0.2147
3rd Support Level 0.2014

See More

52-Week High 2.4200
Fibonacci 61.8% 1.5550
Fibonacci 50% 1.2879
Fibonacci 38.2% 1.0207
Last Price 0.2401
52-Week Low 0.1557

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar